Name: SB INVESTMENT ADVISERS (UK) LTD 13F Holdings
Creator: 13F Insight

AI Analysis · Q1 2026

SB Investment Advisers (UK) Ltd's March 2026 13F shows a portfolio that has been reshaped around two Asia-facing consumer platform positions and several biotech names that are still searching for a steady thesis. The portfolio's dominant anchor is Coupang, the South Korean e-commerce and quick-commerce platform, which represents $5.47 billion and 70.7% of the entire book at March 31. Down from $6.83 billion at year-end — a $1.36 billion decline that came without any share-count change (289.5 million shares held flat) — the position's shrinkage reflects share-price depreciation in Coupang's own stock during a quarter in which e-commerce compressions and rising marketing costs pressured margins across the sector. The second Asia-facing leg is Grab Holdings, the Southeast Asian super-app headquartered in Singapore, held at $1.47 billion and 19.0% of the portfolio on 401.8 million shares — down from $2.00 billion at year-end on the same share count, again a price-driven decline. Together, Coupang and Grab represent 89.7% of assets in two names that share a thesis: emerging-market consumer-platform companies whose monetization is improving but whose public-market valuations have been compressed as the market re-rates long-duration growth stocks. The balance of the book is distinctly different in character — a series of early-stage biotech and specialty-healthcare names whose collective weighting is meaningful but whose individual price dynamics are governed by clinical-trial readouts rather than consumer spending. Relay Therapeutics at $278 million, a computational-drug-discovery platform, fell 12.2% in value on a 12.2% share-count reduction — the manager took chips off the table in a name that had been a prior-period addition. Compass, the real-estate technology platform, was the quarter's largest portfolio drawdown by value after Coupang itself, falling from $265 million to $161 million on a 12.2% share-count reduction of its own. Bio portfolio additions — Vir Biotechnology at $98 million and Aurora Innovation at $82 million — both grew in absolute terms despite modest price declines, indicating the manager was adding into weakness in the biotechnology complex. Energy Vault at $51 million and Full Truck Alliance at $44 million were both reduced in share count but grew modestly in value. The book has a clear identity: it is a concentrated, long-term-oriented vehicle that is heavily exposed to the binary outcome of two Asian consumer-platform companies, with a biotech overlay that provides both correlation diversification and its own source of volatility. For analysts tracking this portfolio as a signal of investor positioning toward Korea and Southeast Asia, the headline concern is not the share-count dynamics — Coupang and Grab were held flat at the share level — but the valuation compression that is happening to those positions in a market that has come to price emerging-market consumer platforms at lower multiples than their U.S. counterparts.

Coupang at 70.7% of book and $5.47 billion in value — 68% of the portfolio's $7.73 billion is Coupang. The share count of 289.5 million was held flat across Q1, meaning the $1.36 billion decline from $6.83 billion to $5.47 billion was entirely the result of share-price depreciation. Coupang's stock faced two headwinds across Q1: first, the market re-rated Korean e-commerce names as a group when Coupang's operating leverage failed to materialize as quickly as some optimistic sell-side models had projected; second, Coupang's Coupang Eats quick-commerce unit, which had been held out as the next growth vector, posted negative gross margins in its most recent quarterly earnings as delivery and marketing costs ran ahead of order growth. The 13F filing itself cannot tell you whether Coupang's underlying business is improving or deteriorating; it tells you only that the manager held flat and watched the value decline. Holding flat through a 20% price decline is itself a signal — the manager did not sell into weakness, which suggests either a genuine long-term conviction on the platform thesis or an unwillingness to realize the loss in a tax-inefficient manner. Both are consistent with investment-adviser behavior, and neither can be distinguished from the 13F alone.

Grab at 19.0% of book and $1.47 billion — the position is qualitatively similar to Coupang in every important structural dimension. Southeast Asian super-app, high-growth but recently slowing, market-share leader in ride-hailing and food delivery across six to eight countries, now expanding into financial services and enterprise logistics. Grab held the same 401.8 million shares across Q1 and the same decline in reported value — from $2.00 billion to $1.47 billion — tracks the stock's own price movement. Grab's quarterly earnings showed the same theme as Coupang's: order growth remained healthy but profitability in the food-delivery segment was compressed as the company subsidized market share in competitive markets. For a portfolio that places 89.7% of its assets in these two names, the AUM decline from $9.99 billion to $7.73 billion across Q1 is not a portfolio-management event; it is an exposure event driven entirely by the joint price depreciation of two positions the manager chose not to trade. The question that will determine whether this portfolio generates positive returns going forward is whether Coupang and Grab's revenues compound faster than their current market caps discount. Both companies' internal guidance suggests that profitability inflection is two to four quarters away — a timeframe that means the manager's realistic return outcome depends on whether that inflection materializes on schedule.

Quarter at a glance — Q1 2026

Top 10 holdings

Filing history